Clinical Trial Update: An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

An open-label Phase 2 clinical study assessing the efficacy and safety of BCD-248 in adults with relapsed/refractory multiple myeloma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCD-248

Snippet

Sponsor: Biocad | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 2 | Status: RECRUITING